Shandong Weigao (01066) Announces Monthly Return on Equity Movements for February 2026

Bulletin Express03-03

Shandong Weigao Group Medical Polymer Company Limited reported that, as of the end of February 2026, the total authorised share capital remained at 4.52 billion H shares and 48.30 million non-listed shares, bringing the aggregate authorised capital to RMB457.06 million.

The total issued share count stood at 4.52 billion, unchanged from the previous month. Among these, 4.48 billion shares were in circulation, while treasury shares rose to 41.58 million. A net 1.46 million shares were repurchased during February at prices between HKD4.99 and HKD5.33, resulting in a corresponding increase in treasury shares. The public float requirement was confirmed to be in compliance with relevant regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment